Docoh
Loading...

ANIP ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.

Company profile

Ticker
ANIP
Exchange
CEO
Patrick Walsh
Employees
Incorporated
Location
Fiscal year end
Former names
BEN ABRAHAM TECHNOLOGIES INC, BIOSANTE PHARMACEUTICALS INC
SEC CIK
IRS number
582301143

ANIP stock data

(
)

Calendar

7 May 21
29 Jul 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 30.07M 30.07M 30.07M 30.07M 30.07M 30.07M
Cash burn (monthly) (positive/no burn) (positive/no burn) (positive/no burn) 859.5K (positive/no burn) (positive/no burn)
Cash used (since last report) n/a n/a n/a 3.4M n/a n/a
Cash remaining n/a n/a n/a 26.67M n/a n/a
Runway (months of cash) n/a n/a n/a 31.0 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 Apr 21 Carey Stephen P. Common Stock Payment of exercise Dispose F No No 31.86 3,042 96.92K 112,500
12 Apr 21 Marken James G. Common Stock Payment of exercise Dispose F No No 31.86 1,878 59.83K 114,321
6 Apr 21 Carey Stephen P. Common Stock Payment of exercise Dispose F No No 33.69 612 20.62K 115,542
6 Apr 21 Marken James G. Common Stock Payment of exercise Dispose F No No 33.69 337 11.35K 116,199
29 Mar 21 Schrepfer Robert W Common Stock Payment of exercise Dispose F No No 32.68 5,566 181.9K 87,477

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Management Discussion
  • In July 2020, we acquired an ANDA and certain related inventories from a private company for total consideration of $4.3 million. The transaction was funded using cash on hand.
  • In May 2020, we entered into an agreement with a private company to purchase an ANDA and API for one currently marketed generic drug product and certain API for $0.2 million. The transaction was funded using cash on hand.
  • In January 2020, we completed the acquisition of the U.S. portfolio of 23 generic products and API and finished goods related to certain of those products from Amerigen Pharmaceuticals, Ltd. ("Amerigen") for a purchase consideration of $56.8 million and up to $25.0 million in contingent payments over the next three years. The product portfolio at the time of the acquisition included ten commercial products, three approved products with launches pending, four filed products and four in-development products as well as a license to commercialize two approved products. The transaction was funded using cash on hand and $15.0 million in borrowings under our $75.0 million Revolver.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: affiliate, Aid, Ampersand, answer, anticompetitive, antitrust, ApexiCon, assumption, attention, aware, Azurity, Baltimore, behavior, beneficial, biopharmaceutical, Bird, built, Bystolic, CDMO, Chairman, Christopher, Circuit, clear, CMS, Concurrently, connection, consummate, consummated, consummation, contemplated, corrupt, Cream, creative, customary, CVS, damage, deadline, default, defect, devote, diminish, Diphenoxylate, disagreement, discover, diverted, empowered, enhance, enhanced, ER, escrow, established, expertise, explore, export, fail, favorable, Fe, Forest, frame, fulfill, Glenmark, grew, grown, GTM, Gutwerg, Hetero, Hightower, identical, imposition, inability, indemnification, indemnifying, India, Indian, innovating, innovative, instability, Investor, issuable, ITA, Judicial, Kroger, leadership, leave, led, liable, light, LJL, lost, Lotion, Maryland, Medicare, merit, motion, moved, multiplied, Mutz, nonfinancial, North, Novitium, Ointment, oncology, oncolytic, Ori, OXISTAT, Pandel, Paragraph, partner, Partnership, pendency, perception, Pfizer, PIPE, placement, political, power, preemption, preferred, prejudice, programmatic, prospective, purposeful, pursuit, rare, recovered, remand, repatriation, replead, reputation, requisite, responsible, Rite, Rule, rupee, Sandoz, Santa, satisfaction, social, staffing, steady, steroid, stipulated, stockholder, strategic, sudden, suffer, terrorism, therewith, Torrent, training, transportation, unique, unrest, VEREGEN, version, voting, waived, Walgreen, Watson, York
Removed: achievement, acute, add, addressed, adjunct, adult, agent, aging, alter, amending, amendment, Amphetamine, antipsychotic, Arthur, atypical, bacteria, BAS, basket, bladder, bond, buy, Carey, ceased, CEO, charge, clarified, clarifying, collective, constipation, context, continuation, contrary, cumulative, declared, deduction, delinquent, demand, departure, diarrhea, diet, disorder, dispose, disqualifying, disruption, diversify, dL, economy, effort, eliminate, Ethyl, evidence, executing, extend, fourth, Glycol, Guide, hypertriglyceridemia, impacting, Impax, imposed, incontinence, increasing, initial, initiate, irrevocably, jiroveci, lack, launched, lead, long, Marken, matured, media, mg, Mixed, mL, modification, modify, monotherapy, mood, NEO, obtained, occasional, occurred, overactive, owed, package, participant, past, Penicillamine, PII, pneumonia, Polyethylene, prepayment, prevention, priority, proven, Przybyl, refinancing, reflective, repurchase, retain, Robert, schizoaffective, schizophrenia, Schrepfer, spread, Stephen, strongly, subset, Sulfamethoxazole, sum, susceptible, suspected, suspend, Suspension, Tartrate, Teva, titled, Tolterodine, Topic, tract, travel, traveler, treatment, triglyceride, Trimethoprim, type, unbilled, uncollectible, unexercised, unprecedented, unsecured, urge, urgency, urinary, USA, USP, vested, World, written